story of the week
Safety and Efficacy of Rituximab vs Dimethyl Fumarate in Patients With Relapsing–Remitting MS or Clinically Isolated Syndrome in Sweden
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
Lancet Neurol 2022 Aug 01;21(8)693-703, A Svenningsson, T Frisell, J Burman, J Salzer, K Fink, S Hallberg, J Hambraeus, M Axelsson, FA Nimer, P Sundström, M Gunnarsson, R Johansson, J Mellergård, I Rosenstein, A Ayad, I Sjöblom, A Risedal, P de Flon, E Gilland, J Lindeberg, F Shawket, F Piehl, J LyckeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.